Matthew Richard Moore is SVP and Chief Business Officer at Arcutis Biotherapeutics, Inc. (ARQT). They have made 1 open-market trade across 1 company since 2023, most recently 2024-05-02.
CIK 0001840191
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ARQT | 150,186 | $4.3M |
Shares reported on the most recent Form 4, priced at the 2024-05-03 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.